Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na\(^+\)) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na\(^+\) channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.
## Sodium Channel Inhibitors & Modulators

### (+)-Kavain
**Cat. No.:** HY-81671

**Bioactivity:** (+)-Kavain, a main kavalactone extracted from *Piper methysticum*, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na⁺ and Ca²⁺ channels [1]. (+)-Kavain has anticonvulsive properties.

**Purity:** 99.98%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg

### (-)-Sparteine sulfate pentahydrate ((-)-Sparteine sulfate salt; Lupinidine sulfate pentahydrate)
**Cat. No.:** HY-B1304

**Bioactivity:** (-)-Sparteine sulfate pentahydrate is a class 1a antiarrhythmic agent and a sodium channel blocker. It is an alkaloid, can chelate the bivalents calcium and magnesium.

**Purity:** 98.0%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 50 mg

### A-803467
**Cat. No.:** HY-11079

**Bioactivity:** A-803467 is a selective Nav1.8 sodium channel blocker with an IC₅₀ of 8 nM; over 100-fold more selective vs. human Nav1.2, 1.3, 1.5 and 1.7.

**Purity:** 97.51%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg

### Ajmaline (Cardiorythmine; (+)-Ajmaline)
**Cat. No.:** HY-B1167

**Bioactivity:** Ajmaline is an alkaloid that is class 1a antiarrhythmic agent.

**Purity:** 99.31%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in Water, 10 mg, 50 mg

### AM-2099
**Cat. No.:** HY-100727

**Bioactivity:** AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC₅₀ of 0.16 μM for human Nav1.7.

**Purity:** 98.0%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### Amiloride (MK-870)
**Cat. No.:** HY-B0285

**Bioactivity:** Amiloride is a relatively selective inhibitor of the epithelial sodium channel (ENaC), used in the management of hypertension and congestive heart failure.

**Purity:** >98%

**Clinical Data:** Launched

**Size:** 100 mg

### Amiloride hydrochloride (MK-870 hydrochloride)
**Cat. No.:** HY-B0285A

**Bioactivity:** Amiloride (hydrochloride) is an epithelial sodium channel (ENaC) inhibitor and a competitive inhibitor of Urokinase-type plasminogen activator (uPA).

**Purity:** 98.0%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 100 mg, 500 mg

### Amiloride hydrochloride dihydrate (MK-870 hydrochloride dihydrate)
**Cat. No.:** HY-B0285B

**Bioactivity:** Amiloride hydrochloride dihydrate is an inhibitor of both Epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA).

**Purity:** 98.56%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 100 mg

### Amitriptyline hydrochloride
**Cat. No.:** HY-B0527A

**Bioactivity:** Amitriptyline Hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA).

**Purity:** 99.64%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in Water, 1 g, 5 g

### Benzamil hydrochloride (Benzylamiloride hydrochloride)
**Cat. No.:** HY-B1546A

**Bioactivity:** Benzamil hydrochloride is a specific blocker of sodium channel (ENaC).

**Purity:** 99.46%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
Bioactivity: Benzocaine shares a common receptor with all other local anesthetics (LAs) in the voltage-gated Na⁺ channel, with an IC₅₀ of 0.8 mM tested with a potential of +30 mV.

Purity: 99.73%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g, 10 g

Bioactivity: Bulleyaconitine A is an analgesic and antiinflammatory drug isolated from Aconitum plants; has several potential targets, including voltage-gated Na⁺ channels.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

Bioactivity: Carbamazepine, a sodium channel blocker, is an anticonvulsant drug. Target: Sodium channel Carbamazepine inhibits the binding of [3H]batrachotoxinin A 20-α-benzoate (BTX-B) to a receptor site of voltage-sensitive sodium channel with IC50 of 131 μM, to decrease the activation of sodium channel ion flux...

Purity: 99.35%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg

Bioactivity: Cariporide (HOE-642) is a selective Na⁺/H⁺ exchange inhibitor.

Purity: 98.57%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: Chlorpromazine D6 hydrochloride is the deuterium labeled Chlorpromazine. Chlorpromazine is an inhibitor of dopamine receptor, 5-HT receptor, potassium channel, sodium channel.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg, 50 mg

Bioactivity: Chlorpromazine Hydrochloride is an antagonist of the dopamine D2, 5HT2A, potassium channel and sodium channel. Chlorpromazine binds with D2 and 5HT2A with Kᵢ of 363 nM and 8.3 nM, respectively.

Purity: 99.83%
Clinical Data: Launched
Size: 1 g, 5 g

Bioactivity: Dibucaine is a local anesthetic of the amide type now generally used for surface anesthesia.

Purity: 99.81%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g, 10 mg

Bioactivity: Dibucaine Hydrochloride is a local anesthetic of the amide type now generally used for surface anesthesia.

Purity: 99.67%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 g, 10 g

Bioactivity: Dyclonine is an oral anesthetic found in Sucrets, an over the counter throat lozenge.

Purity: 99.72%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g, 10 g

Bioactivity: EIPA is a TRPP3 channel inhibitor with an IC₅₀ of 10.5 μM. EIPA also inhibits Na⁺/H⁺-exchanger (NHE) and macropinocytosis.

Purity: 99.73%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg
Eleclazine hydrochloride  
(GS 6615 hydrochloride)  
Cat. No.: HY-16738A  
Bioactivity:  Eleclazine hydrochloride is a novel late Na+ current inhibitor with IC50 value of 0.7 uM.  
Purity:  99.47%  
Clinical Data:  Phase 3  
Size:  10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Eniporide hydrochloride  
(EMD-96785 hydrochloride)  
Cat. No.: HY-106150B  
Bioactivity:  Eniporide hydrochloride (EMD-96785 hydrochloride) is a potent Na+/H+ exchange inhibitor.  
Purity:  99.31%  
Clinical Data:  No Development Reported  
Size:  10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg

Eslicarbazepine acetate  
(BIA 2-093)  
Cat. No.: HY-80703  
Bioactivity:  Eslicarbazepine acetate, an antiepileptic drug, is a dual inhibitor of β-Secretase and voltage-gated sodium channel.  
Purity:  99.48%  
Clinical Data:  Launched  
Size:  10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 500 mg

Flecainide acetate  
(R-818)  
Cat. No.: HY-17429  
Bioactivity:  Flecainide (Tambocor) is a class 1C antiarrhythmic drug especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential. IC50 Value: Target: Nav1.5 channel Flecainide is a class 1C…  
Purity:  99.65%  
Clinical Data:  Launched  
Size:  10mM x 1mL in Water, 10 mg, 50 mg, 100 mg

FR183998 free base  
Cat. No.: HY-100302  
Bioactivity:  FR183998 free base is a potent Na+/H+ exchange inhibitor, with IC50 of 0.3 nM, 3.1 nM and 6.5 nM by measurement of pH change in rat lymphocytes, rat and human platelets, respectively.  
Purity:  >98%  
Clinical Data:  No Development Reported  
Size:  1 mg, 5 mg, 10 mg

Funapide  
(TV 45070; XEN402)  
Cat. No.: HY-16723  
Bioactivity:  Funapide (TV-45070; XEN402) is a potent Sodium Channel Nav1.7 inhibitor.  
Purity:  >98%  
Clinical Data:  No Development Reported  
Size:  250 mg, 500 mg

Ginsenoside Rg3  
(20(S)-Ginsenoside-Rg3; Rg3; S-Ginsenoside Rg3)  
Cat. No.: HY-N0603  
Bioactivity:  Ginsenoside Rg3 is the main component of Red ginseng. Ginsenoside Rg3 inhibits Na+ and hKv1.4 channel with IC50 of 32±2.4 and 32.6±2.2 μM, respectively. Ginsenoside Rg3 also inhibits Aβ levels, NF-κB activity, and COX-2<…  
Purity:  98.0%  
Clinical Data:  Phase 2  
Size:  10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

GNE-131  
Cat. No.: HY-112279  
Bioactivity:  GNE-131 is a potent and selective inhibitor of human sodium channel NaV1.7, with an IC50 of 3 nM.  
Purity:  >98%  
Clinical Data:  No Development Reported  
Size:  10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GS967  
Cat. No.: HY-12593  
Bioactivity:  GS967 (GS-458967) is a potent, and selective inhibitor of cardiac late sodium current (late I_Na) with IC50 values of 0.13 and 0.21 μM for ventricular myocytes and isolated hearts, respectively.  
Purity:  99.96%  
Clinical Data:  No Development Reported  
Size:  10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

ICA-121431  
Cat. No.: HY-16787  
Bioactivity:  ICA-121431 is a nanomolar potent small molecule Nav1.7 channel inhibitor with IC50 of 19 nM for rat Nav1.7, but no inhibition on human, monkey and dog Nav1.7.  
Purity:  98.29%  
Clinical Data:  No Development Reported  
Size:  10mM x 1mL in DMSO, 10 mg, 50 mg
Lamotrigine (LTG; BW430C)  
Cat. No.: HY-80495

Bioactivity: Lamotrigine (BW430C) is a novel anticonvulsant drug for inhibition of 5-HT and sodium channel Target: Sodium Channel. Lamotrigine stabilises presynaptic neuronal membranes by blockade of voltage-dependent sodium channels, thus preventing the release of excitatory neurotransmitters, particularly...

Purity: >98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g

__Bioactivity:__

Lidocaine (Lignocaine)  
Cat. No.: HY-B0185

Bioactivity: Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.

Purity: 99.52%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g, 10 g

__Bioactivity:__

Lidocaine hydrochloride (Lignocaine hydrochloride)  
Cat. No.: HY-B0185A

Bioactivity: Lidocaine HCl salt, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.

Purity: 99.95%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 5 g, 10 g

__Bioactivity:__

Mepivacaine hydrochloride  
Cat. No.: HY-80517A

Bioactivity: Mepivacaine is a tertiary amine used as a local anesthetic.

Purity: 99.83%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g

__Bioactivity:__

Meticrane  
Cat. No.: HY-80908

Bioactivity: Meticrane is a diuretic. Meticrane inhibits the reabsorption of sodium and chloride ions in the distal convoluted tubule. Meticrane is used to treat essential hypertension.

Purity: 98.79%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg

__Bioactivity:__

Mexiletine hydrochloride (KOE-1173 (hydrochloride))  
Cat. No.: HY-A0093

Bioactivity: Mexiletine (hydrochloride) (KOE-1173 (hydrochloride)) is a non-selective voltage-gated sodium channel blocker; Class IB anti-arrhythmic compound.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg

__Bioactivity:__

Moricizine (Moracizine)  
Cat. No.: HY-80615

Bioactivity: Moricizine is an antiarrhythmia agent used primarily for ventricular rhythm disturbances.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

__Bioactivity:__

Myomodulin  
Cat. No.: HY-P0268

Bioactivity: Myomodulin is a neuropeptide present in molluscs, insects, and gastropods.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

__Bioactivity:__

Nav1.7 inhibitor  
Cat. No.: HY-13985

Bioactivity: Nav1.7 inhibitor is a potent Nav1.7 inhibitor. IC50 value: Target: Nav1.7 Preparation of sulfonamide derivatives as Nav1.7 inhibitors By Brown, Alan Daniel; Rawson, David James; Storer, Robert Ian; Swain, Nigel Alan From PCT Int. Appl. (2012), WO 2012007868 A2 20120119.

Purity: 98.81%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

__Bioactivity:__

Nav1.7-IN-2  
Cat. No.: HY-19366

Bioactivity: Nav1.7-IN-2 is an inhibitor of voltage-gated sodium channels (Nav), in particular Nav 1.7, with IC50 of 80 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
Nav1.7-IN-3
Cat. No.: HY-101789

Bioactivity: Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC$_{50}$ of 8 nM. Pain relief. Limited CNS penetration [1].
Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg

NHE3-IN-1
Cat. No.: HY-100325

Bioactivity: NHE3-IN-1 is a sodium/proton exchanger type 3 (NHE-3) inhibitor extracted from patent WO 2011019784 A1.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nicainoprol
(RU-42924)
Cat. No.: HY-100572

Bioactivity: Nicainoprol is a fast- sodium-channel blocking drug, which is a potent antiarrhythmic agent.
Purity: 99.48%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg

Oxcarbazepine
(GP 47680)
Cat. No.: HY-B0114

Bioactivity: Oxcarbazepine (GP 47680) inhibits the binding of [3H]BTX to sodium channels with IC$_{50}$ of 160 μM and also inhibits the influx of 22Na$^+$ into rat brain synaptosomes with IC$_{50}$ about 100 μM.
Purity: 99.82%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg

PF 04531083
Cat. No.: HY-105283

Bioactivity: PF 04531083 is a selective Na$_{v}$1.8 blocker, and used for the research of neuropathic/inflammatory pain.
Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PF 05089771
Cat. No.: HY-12883

Bioactivity: PF 05089771 is a Nav1.7 channel blocker extracted from patent WO/2010/079443 A1, compound example 788, has an IC50 of 8.6 nM.
Purity: 99.32%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

PF-01247324
Cat. No.: HY-101383

Bioactivity: PF-01247324 is a selective and orally bioavailable Na$_{v}$1.8 channel blocker with an IC$_{50}$ of 196 nM for recombinant human Na$_{v}$1.8 channel.
Purity: 99.42%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-05241328
Cat. No.: HY-103623

Bioactivity: PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels (Nav1.7), with an IC$_{50}$ of 31 nM.
Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

PF-06305591
Cat. No.: HY-114301

Bioactivity: PF-06305591 is a potent and highly selective voltage gated sodium channel Nav1.8 blocker, with an IC$_{50}$ of 15 nM. An excellent preclinical in vitro ADME and safety profile [1].
Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

PF-06869206
Cat. No.: HY-112065

Bioactivity: PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC$_{50}$ of 380 nM.
Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg
**Phenytoin**  
(5,5-Diphenylhydantoin)  
Cat. No.: HY-80448  

**Bioactivity:** Phenytoin is an inactive voltage-gated sodium channel stabilizer.

**Purity:** 99.91%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 1 g, 5 g

**Phenytoin sodium**  
(5,5-Diphenylhydantoin sodium salt)  
Cat. No.: HY-80448A  

**Bioactivity:** Phenytoin sodium is an inactive voltage-gated sodium channel stabilizer.

**Purity:** 99.91%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 1 g, 5 g

**Propafenone D7 hydrochloride**  
(SA-79 (D7 hydrochloride))  
Cat. No.: HY-80432A  

**Bioactivity:** Propafenone (D7 hydrochloride) (SA-79 (D7 hydrochloride)) is the deuterium labeled Propafenone, which is a classic anti-arrhythmic medication.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg, 10 mg

**Propafenone hydrochloride**  
(SA-79 (hydrochloride))  
Cat. No.: HY-80432A  

**Bioactivity:** Propafenone (hydrochloride) (SA-79 (hydrochloride)) is a class of anti-arrhythmic medication, which treats illnesses associated with rapid heart beats such as atrial and ventricular arrhythmias.

**Purity:** 99.70%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 1 g, 5 g

**Proparacaine Hydrochloride**  
(Proxymetacaine Hydrochloride)  
Cat. No.: HY-66012  

**Bioactivity:** Proparacaine Hydrochloride is a voltage-gated sodium channels antagonist with ED50 of 3.4 mM.

**Purity:** 99.56%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 100 mg

**Propoxycaine hydrochloride**  
Cat. No.: HY-B1243  

**Bioactivity:** Propoxycaine hydrochloride is the hydrochloride salt form of Propoxycaine, a para-aminobenzoic acid ester with local anesthetic activity. Target: sodium channel Propoxycaine binds to and inhibits voltage-gated sodium channels, thereby inhibiting the ionic flux required for the initiation and...

**Purity:** 99.91%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 1 g, 5 g

**Ranolazine**  
(CVT 303, RS 43285-003)  
Cat. No.: HY-80280  

**Bioactivity:** Ranolazine is an antianginal medication.

**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg

**Ranolazine dihydrochloride**  
(RS 43285)  
Cat. No.: HY-17401  

**Bioactivity:** Ranolazine(RS-43285) is an antianginal agent with antiarrhythmic properties that achieves its effects via a novel mechanism of action (inhibition of the late phase of the inward sodium current), without affecting heart rate or blood pressure (BP). ICS0 value: Target: sodium-dependent calcium...

**Purity:** 99.92%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in Water, 100 mg, 200 mg, 500 mg, 1 g, 5 g

**Raxatrigine**  
(GSK-1014802; CNV1014802)  
Cat. No.: HY-12796  

**Bioactivity:** Raxatrigine (GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.

**Purity:** 99.47%  
**Clinical Data:** Phase 2  
**Size:** 5 mg, 10 mg, 50 mg, 100 mg

**Raxatrigine hydrochloride**  
(GSK-1014802 hydrochloride; CNV1014802 (hydrochloride))  
Cat. No.: HY-12796A  

**Bioactivity:** Raxatrigine hydrochloride (GSK-1014802 hydrochloride) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.

**Purity:** 98.69%  
**Clinical Data:** Phase 2  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
Bioactivity: Riluzole is an anticonvulsant drug and belongs to the family of use-dependent Na⁺ channel blocker which can also inhibit GABA uptake with an IC₅₀ of 43 μM.

Purity: 98.03%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg, 1 g

Bioactivity: Riluzole hydrochloride is an anticonvulsant drug and belongs to the family of use-dependent Na⁺ channel blocker which can also inhibit GABA uptake with an IC₅₀ of 43 μM.

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 50 mg, 100 mg, 500 mg

Bioactivity: Rimeporide (EMD-87580) is a potent and selective inhibitor of the Na⁺/H⁺ exchanger (NHE-1).

Purity: 98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bioactivity: Rimeporide hydrochloride (EMD-87580 hydrochloride) is a potent and selective inhibitor of the Na⁺/H⁺ exchanger (NHE-1).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bioactivity: Ropivacaine hydrochloride monohydrate is an anaesthetic agent and blocks impulse conduction in nerve fibres through inhibiting sodium ion influx reversibly.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg

Bioactivity: Sodium Channel inhibitor 1 is one of 3-Oxoisooxindoline-1-carboxamides, is a novel and selective voltage-gated sodium channel for pain treatment.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: Sodium Channel inhibitor 2 is a sodium channel blocker extracted from patent WO 2004011439 A2, compound 3c.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Bioactivity: Tenapanor is an inhibitor of the Na⁺/H⁺ exchanger NHE3 with IC₅₀ values of 5 and 10 nM against human and Rat NHE3, respectively.

Purity: 98.80%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bioactivity: Tetracaine is a topical local anesthetic for the eyes; works by interfering with entry of sodium ions into nerve cells.

Purity: 98.03%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Bioactivity</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triamterene</td>
<td>HY-80575</td>
<td>Triamterene blocks epithelial Na+ channel (ENaC) in a voltage-dependent manner, which was used as a mild diuretic.</td>
<td>&gt;98%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 100 mg, 500 mg</td>
</tr>
<tr>
<td>Triamterene D5</td>
<td>HY-80575S</td>
<td>Triamterene D5 is deuterium labeled Triamterene, which can block epithelial Na+ channel (ENaC) in a voltage-dependent manner, which was used as a mild diuretic.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>5 mg, 10 mg</td>
</tr>
<tr>
<td>Trichlormethiazide</td>
<td>HY-80235</td>
<td>Trichlormethiazide is a thiazide diuretic with properties similar to those of hydrochlorothiazide.</td>
<td>98.67%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 1 g, 5 g</td>
</tr>
<tr>
<td>Vinpocetine (Cavinton; Ethyl apovincaminate)</td>
<td>HY-13295</td>
<td>Vinpocetine(Cavinton; Ethyl apovincaminate) is a selective for PDE1 (IC50 = 21 μM). Also blocks voltage-gated Na+ channels. IC50 value: Target: PDE1; Na+ channel</td>
<td>99.43%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg</td>
</tr>
<tr>
<td>XEN907</td>
<td>HY-19958</td>
<td>XEN907 is a novel spiroxindole NaV1.7 blocker, inhibits hNaV1.7 with IC50 of 3 nM.</td>
<td>99.95%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg</td>
</tr>
<tr>
<td>YM758</td>
<td>HY-U00309</td>
<td>YM758 is a “funny” I, channel (I, channel) inhibitor.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td>Zonisamide (AD 810; CI 912)</td>
<td>HY-80124</td>
<td>Zonisamide is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug.</td>
<td>99.72%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 200 mg, 500 mg</td>
</tr>
<tr>
<td>Zonisamide sodium (AD 810 sodium; CI 912 sodium)</td>
<td>HY-80124A</td>
<td>Zonisamide sodium is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug.</td>
<td>&gt;98%</td>
<td>Launched</td>
<td>200 mg, 500 mg</td>
</tr>
</tbody>
</table>